Currently out of the existing stock ratings of Douglas Tsao, 592 are a BUY (84.21%), 3 are a SELL (0.43%), 108 are a HOLD (15.36%).

Douglas Tsao

Work Performance Price Targets & Ratings Chart

Analyst Douglas Tsao, carries an average stock price target met ratio of 47.05% that have a potential upside of 39.05% achieved within 253 days. Previously, Douglas Tsao worked at BARCLAYS.

Douglas Tsao’s has documented 1,314 price targets and ratings displayed on 53 stocks. The coverage was on Healthcare, Energy sectors.

Most recent stock forecast was given on PCRX, Pacira Pharmaceuticals at 01-Jul-2026.

Wall Street Analyst Douglas Tsao

Analyst best performing recommendations are on PTGX (PROTAGONIST THERAPEUTICS).
The best stock recommendation documented was for PTGX (PROTAGONIST THERAPEUTICS) at 10/8/2025. The price target of $80 was fulfilled within 2 days with a profit of $14.7 (22.51%) receiving and performance score of 112.56.

Average potential price target upside

of $233.25 (82.93%) on PRAX (PRAXIS PRECISION MEDICINES ).
of $77.12 (18.27%) on ARGX (ARGENX NV ADR).
of $22.89 (56.56%) on IRON (DISC MEDICINE).

CHMA Chiasma MYL Viatris JAZZ Jazz Pharmaceuticals PLC MNK Mallinckrodt plc PCRX Pacira Pharmaceuticals TEVA Teva Pharma Industries Ltd ADR AGN Allergan plc ALKS Alkermes Plc CERE Cerevel Therapeutics Holdings CHRS Coherus BioSciences CRL Charles River Laboratories CRNX Crinetics Pharmaceuticals ENDP Endo International PLC EOLS Evolus IMVT Immunovant MNTA Momenta Pharmaceuticals OSMT Osmotica Pharmaceuticals plc PRAX Praxis Precision Medicines PRGO Perrigo Company PLC PTGX Protagonist Therapeutics RDUS Schnitzer Steel Industries RVNC Revance The SAGE Sage Therapeutic ROIV Roivant Sciences Ltd TBPH Theravance Biopharma TRVN Trevena TXMD TherapeuticsMD ARGX argenx NV ADR AMYT Amryt Pharma Holdings Ltd DARE Dare Bioscience APLS Apellis Pharmaceuticals CABA Cabaletta Bio ELYM Eliem Therapeutics EVO Evotec SE ADR NERV Minerva Neurosciences OTLK OUTLOOK THERAPEUTICS INC RVLP RVL Pharmaceuticals PLC RZLT Rezolute VRDN Viridian Therapeutics MRNS Marinus Pharmaceuticals SCPH Scpharmaceuticals AMAG AMAG Pharmaceuticals ARQT Arcutis Biotherapeutics BHVN Biohaven Pharmaceutical Holding Co Ltd XENE Xenon Pharmaceuticals IRON Disc Medicine NMRA Neumora Therapeutics ARCT Arcturus Therapeutics Holdings AEON AEON Biopharma VTRS Viatris AM Antero Midstream Partners LP DERM Journey Medical Corp SA Seabridge Gold

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Brandon Folkes (HC WAINWRIGHT)